» Articles » PMID: 7053846

Effects of Liposome Structure and Lipid Composition on the Activation of the Tumoricidal Properties of Macrophages by Liposomes Containing Muramyl Dipeptide

Overview
Journal Cancer Res
Specialty Oncology
Date 1982 Jan 1
PMID 7053846
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Various vesicle structures and lipid compositions have been studied to identify the optimal type of liposome for delivery of the macrophage-activating agent muramyl dipeptide (MDP) to macrophages. Evaluation of the ability of liposomes to be phagocytosed by macrophages established that optimal initial rates of engulfment were obtained when multilamellar vesicles (MLV) composed of distearoylphosphatidylcholine (18:0 PC): phosphatidylserine (PS) (7:3 mol ratio) were used. MLV composed exclusively of 18:0 PC were phagocytosed at rates greater than or equal to those of MLV composed of egg phosphatidylcholine (PC):PS, whereas MLV composed only of egg PC were very poorly phagocytosed. Although phagocytosis was enhanced by incorporation of PS into MLV, the inclusion of PS brought about significant enhancement in liposome permeability in the presence of serum. The inclusion of PS, however, was a requirement for the delivery of MLV to the lungs following i.v. injection into mice whether used in conjunction with 18:0 PC or egg PC. Activation of macrophages to become tumoricidal against syngeneic tumor cells wtih liposome-encapsulated MDP was superior in both degree and duration when MLV composed of 18:0 PC:PS (7:3 mol ratio) were used. MLV were found to be superior to large unilamellar vesicles containing equal amounts of lipid and entrapped MDP. On the other hand, higher levels of macrophage activation were obtained when an equivalent amount of a lipophilic MDP derivative, muramyltripeptide:phosphatidylethanolamine, was incorporated into the liposome bilayer irrespective of whether the adjuvant was incorporated in liposomes composed of 18:0 PC:PS or egg PC:PS.

Citing Articles

Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement.

Lalhmangaihzuala S, Vanlaldinpuia K, Khiangte V, Laldinpuii Z, Liana T, Lalhriatpuia C Mol Divers. 2024; 28(6):4553-4579.

PMID: 38554170 DOI: 10.1007/s11030-024-10810-2.


Etiology of lipid-laden macrophages in the lung.

Stevenson E, Smith L, Wilkinson M, Lee S, Gow A Int Immunopharmacol. 2023; 123:110719.

PMID: 37595492 PMC: 10734282. DOI: 10.1016/j.intimp.2023.110719.


Carbohydrate-based drugs launched during 20002021.

Cao X, Du X, Jiao H, An Q, Chen R, Fang P Acta Pharm Sin B. 2022; 12(10):3783-3821.

PMID: 36213536 PMC: 9532563. DOI: 10.1016/j.apsb.2022.05.020.


Harnessing the Therapeutic Potential of Biomacromolecules through Intracellular Delivery of Nucleic Acids, Peptides, and Proteins.

Tian Y, Tirrell M, LaBelle J Adv Healthc Mater. 2022; 11(12):e2102600.

PMID: 35285167 PMC: 9232950. DOI: 10.1002/adhm.202102600.


A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives.

Liu P, Chen G, Zhang J Molecules. 2022; 27(4).

PMID: 35209162 PMC: 8879473. DOI: 10.3390/molecules27041372.